Aerie Pharmaceuticals (NASDAQ:AERI) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 6th. Analysts expect Aerie Pharmaceuticals to post earnings of ($1.33) per share for the quarter.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.16). The company had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $1.16 million. On average, analysts expect Aerie Pharmaceuticals to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of NASDAQ AERI opened at $53.84 on Monday. Aerie Pharmaceuticals has a 1 year low of $47.06 and a 1 year high of $74.75. The company has a market cap of $2.43 billion, a P/E ratio of -15.98 and a beta of 0.99. The company has a current ratio of 10.27, a quick ratio of 10.07 and a debt-to-equity ratio of 0.64.
In other news, COO Thomas A. Mitro sold 190,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $60.27, for a total value of $11,451,300.00. Following the transaction, the chief operating officer now owns 234,147 shares of the company’s stock, valued at approximately $14,112,039.69. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Richard J. Rubino sold 66,605 shares of the firm’s stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $60.23, for a total transaction of $4,011,619.15. Following the completion of the transaction, the chief financial officer now directly owns 334,236 shares in the company, valued at approximately $20,131,034.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 324,117 shares of company stock worth $19,459,226. 10.53% of the stock is owned by company insiders.
A number of brokerages recently issued reports on AERI. Needham & Company LLC set a $86.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, July 13th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 14th. BidaskClub lowered shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 7th. HC Wainwright set a $78.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $86.00 price target on shares of Aerie Pharmaceuticals in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $82.30.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.